FALSE STROKES DUBAI, UAE (CMC): Captain Jason Holder has hailed Darren Bravo’s eighth Test century in difficult final day circumstances and said his entire team had showed plenty character, despite their 56-run defeat to Pakistan in the day/night opening Test here yesterday. Bravo stroked 116 at the Dubai International Stadium as West Indies, chasing 346 for victory, came up short on 289 in their second innings to fall 0-1 behind in the three-Test series. “It was a quality innings and he batted really well in both the first and second innings,” Holder told reporters afterwards. “I think he showed a lot of maturity in both those innings. He spent some time, he gave himself a really good chance to get a score and you could see the determination on his face and in his expressions and even his body language I thought it was very, very positive. “Hopefully we can continue in this vein and keep Darren Bravo leading our batting.” “That was obviously a crucial moment there. Bravo was the set batsman, he’d played beautifully up until that point, but it was tough coming out of the rough with Yasir Shah,” he explained. “I thought he bowled really well, he was very, very challenging and he made it difficult for us to score and also defend. “If you look back at it, you see a lot of things in hindsight, but obviously at the moment when Bravo got out we would’ve probably asked him to go on a little longer.” West Indies were always up against it once they conceded a lead of 222 on first innings after Pakistan had piled up a mammoth 579 for three declared in their first innings. However, with leg-spinner Devendra Bishoo taking eight for 49, the Windies bundled out Pakistan for 123 in their second innings to open up the game. Holder said the batting effort from his side in both innings and the bowling in the Pakistan second innings, was cause for encouragement. “I am obviously disappointed that we lost. At the end of the day it is still a loss, but having said that there are lots of positives I can take from this game,” he pointed out. “One thing is I am really proud of the guys for the way they fought. I must commend the guys, they stuck it straight through to the end, all the bowlers gave a really big effort on a pitch that didn’t give much assistance to them and I can’t really fault the effort of the guys. “I just think it was a very, very good team effort. Unfortunately we didn’t get over the line and unfortunately we didn’t save the game, but there are a hell of a lot of positives to take from this game.” Scoreboard PAKISTAN 1st Innings 579-3 decl. WEST INDIES 1st Innings 357 PAKISTAN 2nd innings 123 WEST INDIES 2nd Innings (target: 346) (overnight 95 for two) K Brathwaite b Mohammad Amir 6 L Johnson lbw b Mohammad Amir 47 D Bravo c & b Yasir Shah 116 M Samuels c wkp Sarfraz Ahmed b Mohammad Amir 4 J Blackwood lbw b Mohammad Nawaz 15 R Chase b Yasir Shah 35 +S Dowrich b Wahab Riaz 0 *J Holder not out 40 D Bishoo lbw b Mohammad Nawaz 3 M Cummins run out 1 S Gabriel run out 1 Extras (b5, lb7, w5, nb4) 21 TOTAL (all out, 109 overs) 289 Fall of wickets: 1-27, 2-87, 3-95, 4-116, 5-193, 6-194, 7-263, 8-276, 9-277, 10-289. Bowling: Mohammad Amir 23-5-63-3 (w1), Sohail Khan 10-1-22-0, Yasir Shah 41-6-113-2, Mohammad Nawaz 18-4-32-2, Wahab Riaz 17-1-47-1 (nb4). Result: Pakistan won by 56 runs. Series: Pakistan lead three-match series 1-0. Man-of-the-Match: Azhar Ali. CRUCIAL MOMENT Unbeaten on 26 at the start with West Indies on 95 for two, the left-hander survived the loss of veteran partner Marlon Samuels for four to the first ball of the day, to keep Pakistan at bay. All told, he faced 249 balls in a marathon 63/4 hours at the crease and struck 10 fours and a six. He anchored half-century stands with Roston Chase (35) and Jason Holder (40 not out), to carry West Indies’ victory bid late into the final session. However, with perhaps one of his few false strokes of the innings, he mistimed a drive back to Yasir Shah in the final hour to be seventh out at 263 and Holder said that dismissal was the turning point in the contest.
In 1983 Liverpool were English champions and had reached an agreement to sign Brondby’s teenage sensation Michael Laudrup, but it fell apart as retrofootballblog.com explains.He wanted to join them, he was a Liverpool fan, but ultimately the deal didn’t materialise because Laudrup didn’t like it when the club attempted to alter the agreement.Personal terms were settled, but the Reds came back and said they wanted the contract changed so the player’s deal ran for four years instead of three.Laudrup said no, Liverpool didn’t relent and the 19-year-old joined Juventus before spells at both Barcelona and Real Madrid in addition to starring for Denmark at the 1986 World Cup.Liverpool didn’t exactly regret the decision because they won the treble in the 1983/84 season, clinching a fourth European Cup in seven years, but a front line of Laudrup, Kenny Dalglish and Ian Rush would have been frightening, right?He really was that good and you don’t have to look very hard to find a who’s who of football legends like Romario, Pep Guardiola and Lionel Messi, talking about the playmaker’s incredible talent.READ MORE: A brilliant story involving Michael Laudrup and the king of SpainThe comical situation that led to Chelsea signing their league winning captainRead more at RetroFootballBlog.com Liverpool’s change of heart over Laudrup’s contract resulted in Juventus signing him instead 1
Alzheimer’s disease is expected to triple in prevalence by 2050, affecting 115 million people worldwide. There’s no cure or treatment yet for the fatal neurodegenerative condition, but many physicians and scientists suggest that drugs that have failed so far will work if given much earlier, a strategy that requires diagnosing the disease before symptoms develop. Now, a research team has discovered a group of molecules in the blood that they say can predict with 90% accuracy whether older people will develop the disease over the course of 2 to 3 years. Although such a test is not ready for general use, and may never be, the technique could still help recruit people most at risk of developing Alzheimer’s into clinical trials of possible treatments.Beyond an autopsy analysis of a person’s brain, two accepted methods of diagnosing Alzheimer’s disease exist at present, says Douglas Galasko, a neuroscientist at the University of California (UC), San Diego, School of Medicine. One technique uses brain imaging to detect the hallmark protein found in plaques in brain tissue which marks the disorder. The other measures levels of these proteins by extracting fluid from the spinal cord. Few people wish to undergo that painful procedure, however, and because both techniques are expensive and not terribly accurate, particularly at the earliest stages of Alzheimer’s, researchers have spent decades looking for a less invasive, more affordable blood-based test. So far, however, these efforts have produced “no success,” Galasko says.To ferret out blood molecules that might signal the onset of Alzheimer’s disease in elderly people, a team from Georgetown University and several other institutions recruited several hundred senior citizens age 70 and up from retirement communities in New York and California. They took blood samples and shipped them on ice to a lab with a mass spectrometer in order to precisely quantify the blood samples’ chemical makeup.Sign up for our daily newsletterGet more great content like this delivered right to you!Country *AfghanistanAland IslandsAlbaniaAlgeriaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, The Democratic Republic of theCook IslandsCosta RicaCote D’IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and Mcdonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People’s Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People’s Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, The Former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMartiniqueMauritaniaMauritiusMayotteMexicoMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorwayOmanPakistanPalestinianPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalQatarReunionRomaniaRussian FederationRWANDASaint Barthélemy Saint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofVietnamVirgin Islands, BritishWallis and FutunaWestern SaharaYemenZambiaZimbabweI also wish to receive emails from AAAS/Science and Science advertisers, including information on products, services and special offers which may include but are not limited to news, careers information & upcoming events.Required fields are included by an asterisk(*)Over the next 3 years, the researchers tracked the seniors’ mental health, and identified 53 people with mild cognitive impairment or Alzheimer’s disease, 18 of whom had not displayed any symptoms at the beginning of the study. At the 3-year mark, they returned to the analyses of the blood samples and compared those of the people who had developed symptoms of Alzheimer’s disease with 53 of the elderly people from the group who remained healthy. In the group whose mental health had declined, there were significant alterations in the blood levels of 10 different chemicals, including fatty molecules called phospholipids, which help keep cell membranes in the brain and body intact, the team reports online today in Nature Medicine.To check that its observations weren’t just a random event, the team tested whether the same altered pattern could predict whether 41 other elderly people from the same retirement communities had developed Alzheimer’s disease, and found that it hit the mark 90% of the time. Despite these encouraging findings, senior author Howard Federoff, a neuroscientist at Georgetown University in Washington, D.C., says the test needs much more validation. “This is a new observation, and it’s imperative that it be extended and replicated on an independent group of individuals.”Others are equally cautious. “We won’t know if it’s going to be a big deal or not” until other groups replicate the study, agrees Michael Weiner, a neuroscientist at UC San Francisco. The population of people with Alzheimer’s disease is so diverse, and is fraught with so many health problems, that it may turn out that although the test is good at detecting people who are at risk for cognitive decline, it will pick up too many other conditions in the process to be useful as a diagnostic tool. If that’s the case, the test could still be used to screen people for preventative clinical trials of Alzheimer’s drugs for the disease, he says.That Federoff and colleagues validated their findings in an independent group of elderly people is “impressive,” says Robert Green, a medical geneticist at Harvard University. Many such studies “have turned out to be a flash in the pan,” he says, but the new study “is more sophisticated than most.”*Correction, 17 March, 4:06 p.m.: This story has been corrected to reflect that only one of Alzheimer’s two hallmark protein deposits can currently be imaged in the brain for diagnostic purposes.